Taboada, A* Dotaz Zobrazit nápovědu

Přesná shoda Sémantické

6 záznamů v Medvik

Článek online

Dexamethasone doses in patients with COVID-19 and hypoxia: A systematic review and meta-analysis

Munch, Marie Warrer
Autor Munch, Marie Warrer ORCID Department of Intensive Care, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark Collaboration for Research in Intensive Care (CRIC), Copenhagen, Denmark
Granholm, Anders
Autor Granholm, Anders ORCID Department of Intensive Care, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark Collaboration for Research in Intensive Care (CRIC), Copenhagen, Denmark
Maláska, Jan
Autor Maláska, Jan ORCID Department of Paediatric Anaesthesiology and Intensive Care Medicine, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic Department of Simulation Medicine, Faculty of Medicine, Masaryk University, Brno, Czech Republic 2nd Department of Anaesthesiology University Hospital Brno, Brno, Czech Republic
Stašek, Jan
Autor Stašek, Jan Department of Internal Medicine and Cardiology, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic
Rodriguez, Pablo O
Autor Rodriguez, Pablo O Pulmonary and Critical Care Medicine, Instituto Universitario CEMIC (Centro de Educación Médica e Investigación Clínica), Buenos Aires, Argentina
Pitre, Tyler
Autor Pitre, Tyler Department of Medicine, McMaster University, Hamilton, Ontario, Canada Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
Wilson, Rebecca
Autor Wilson, Rebecca Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England NIHR Applied Research Collaboration West (ARC West), University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, England
Savović, Jelena
Autor Savović, Jelena Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England NIHR Applied Research Collaboration West (ARC West), University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, England
Rochwerg, Bram
Autor Rochwerg, Bram Department of Medicine, McMaster University, Hamilton, Ontario, Canada Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada
Svobodnik, Adam
Autor Svobodnik, Adam Department of Pharmacology/CZECRIN, Faculty of Medicine, Masaryk University, Brno, Czech Republic

Acta anaesthesiologica Scandinavica. 2024 ; 68 (2) : 146-166. [pub] 20231026

Acta Anaesthesiol Scand
ISSN 1399-6576
Medvik
Zdroj

BACKGROUND: The optimal dose of dexamethasone for severe/critical COVID-19 is uncertain. We compared higher versus standard doses of dexamethasone in adults with COVID-19 and hypoxia. METHODS: We searched PubMed and trial registers until 23 June 2023 for randomised clinical trials comparing higher (>6 mg) versus standard doses (6 mg) of dexamethasone in adults with COVID-19 and hypoxia. The primary outcome was mortality at 1 month. Secondary outcomes were mortality closest to 90 days; days alive without life support; and the occurrence of serious adverse events/reactions (SAEs/SARs) closest to 1 month. We assessed the risk of bias using the Cochrane RoB2 tool, risk of random errors using trial sequential analysis, and certainty of evidence using Grading of Recommendations Assessment, Development and Evaluation (GRADE). RESULTS: We included eight trials (2478 participants), of which four (1293 participants) had low risk of bias. Higher doses of dexamethasone probably resulted in little to no difference in mortality at 1 month (relative risk [RR] 0.97, 95% CI: 0.79-1.19), mortality closest to Day 90 (RR 1.01, 95% CI: 0.86-1.20), and SAEs/SARs (RR 1.00, 95% CI: 0.97-1.02). Higher doses of dexamethasone probably increased the number of days alive without invasive mechanical ventilation and circulatory support but had no effect on days alive without renal replacement therapy. CONCLUSIONS: Based on low to moderate certainty evidence, higher versus standard doses of dexamethasone probably result in little to no difference in mortality, SAEs/SARs, and days alive without renal replacement therapy, but probably increase the number of days alive without invasive mechanical ventilation and circulatory support.

Článek online

Simultaneous Detection of Antigen and Antibodies of African Swine Fever in a Novel Combo Lateral Flow Assay

Vaccines. 2024 ; 12 (3) : . [pub] 20240314

Vaccines (Basel)
ISSN 2076-393X
Medvik
Zdroj

African swine fever (ASF) is a contagious disease of wild boar and domestic pigs notifiable to the World Organisation for Animal Health due to its high socio-economic impact. ASF is caused by the complex ASF virus (ASFV), and it can present different clinical manifestations that can be confused with other diseases; for this reason, laboratory testing is necessary for the proper diagnosis of clinically suspected animals. Despite the efforts put into it over decades, no treatment or safe vaccine is globally available, and disease control is based on early diagnosis and the implementation of strict biosecurity measures. In this context, rapid tests have the potential to accelerate and facilitate the identification of infected animals by giving fast on-site results. In this work, we improved the available point-of-care assays for the diagnosis of the disease by the development of a more specific antigen test and a more sensitive antibody test. This antibody detection test allowed for the earlier detection of infected animals than two commercial indirect ELISAs (statistically significant). Moreover, we developed a combined dual rapid test, unifying, in the same cassette, an antigen detection strip and an antibody detection strip. In this study, we confirmed that this combo approach is a useful tool for implementing rapid tests in the field since it increases the percentage of positive samples detected, even when PCR turns negative, while maintaining a good specificity.